Department of Ophthalmology, Centro Hospitalar e Universitário São João, Porto, Portugal,
Department of Ophthalmology, Centro Hospitalar e Universitário São João, Porto, Portugal.
Ophthalmic Res. 2021;64(2):290-296. doi: 10.1159/000511592. Epub 2020 Sep 15.
This study aimed to evaluate the longitudinal changes in retinal layer thickness in patients treated with hydroxychloroquine without retinal toxicity.
This is a longitudinal retrospective study of patients taking hydroxychloroquine followed in a hydroxychloroquine retinal toxicity screening program of a tertiary hospital between January 2010 and April 2019. Patients who performed 2 optical coherence tomography (OCT) scans at least 1 year apart were included. All subjects with hydroxychloroquine suspected or confirmed retinal toxicity, glaucoma, retinal pathology, or poor segmented images were excluded. Spectral-domain optical coherence tomography (Spectralis HRA-OCT, Heidelberg) was used to evaluate the macular area. Automatically segmented ETDRS retinal thickness maps were compared between the first and the last OCT evaluation available. Full retina (FR), inner retina (IRL), ganglion cells (GCL), inner nuclear (INL), and outer retina (ORL) layer thicknesses were measured in the foveolar, paracentral, and peripheral area.
The population included 144 eyes of 144 patients. The mean interval between OCT scans was 38.1 ± 18.4 months, and the mean cumulative dose was 406.9 ± 223.9 g. Foveolar (p = 0.040, p = 0.006, and p = 0.001, respectively) and paracentral (p = 0.006, p = 0.001, and p = 0.005, respectively) FR, IRL, and GCL decreased overtime. No differences were found in INL or ORL. A very weak correlation was found between age and foveal IRL change overtime (p = 0.037; R = 0.175), as well as between the hydroxychloroquine time of use and foveal GCL variation (p = 0.032; R = 0.179).
Hydroxychloroquine was found to cause progressive thinning of the inner retinal layers, specifically in the GCL of the foveolar and paracentral areas, but no changes were observed in the outer retina.
本研究旨在评估未发生视网膜毒性的羟氯喹治疗患者的视网膜层厚度的纵向变化。
这是一项回顾性纵向研究,纳入 2010 年 1 月至 2019 年 4 月在一家三级医院羟氯喹视网膜毒性筛查项目中接受羟氯喹治疗的患者。入选标准为至少行 2 次 OCT 检查,且两次检查间隔至少 1 年。排除有羟氯喹疑似或确诊视网膜毒性、青光眼、视网膜病变或图像分割不佳的患者。采用频域光学相干断层扫描(Spectralis HRA-OCT,Heidelberg)评估黄斑区。比较首次和末次 OCT 评估时可获得的自动分割的 ETDRS 视网膜厚度图。在中心凹、旁中心和周边区域测量全视网膜(FR)、内视网膜(IRL)、神经节细胞(GCL)、内核层(INL)和外视网膜(ORL)的厚度。
共纳入 144 例患者的 144 只眼。两次 OCT 检查的平均间隔为 38.1±18.4 个月,平均累积剂量为 406.9±223.9g。中心凹(p=0.040,p=0.006,p=0.001)和旁中心凹(p=0.006,p=0.001,p=0.005)FR、IRL 和 GCL 随时间逐渐变薄。INL 和 ORL 无变化。年龄与中心凹 IRL 随时间的变化呈弱相关(p=0.037;R=0.175),羟氯喹用药时间与中心凹 GCL 变化呈弱相关(p=0.032;R=0.179)。
羟氯喹可导致内视网膜层,特别是中心凹和旁中心凹的 GCL 进行性变薄,但外视网膜无变化。